IAS officer and Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe, who has made headlines for the hygiene crackdown against top eateries in Mumbai, now appears set to focus on the ‘D’ in FDA.

In a post on X, the IAS officer has said that the “most expensive part of a hospital bill may never touch the hospital at all”. “A patient admitted for care has no way of knowing whether the price on a medical consumable reflects its actual cost or a markup fixed long before it ever reached the ward. That gap in information is, at its core, a public health issue,” he has said.

Tukaram Mundhe’s X post

In fact, in an interview with recently, Mundhe was asked if the FDA was planning a crackdown on drug facilities after its food safety action</strong&gt;.

Story continues below.
Subscribe to see fewer ads.

In his response, Mundhe detailed how pricing of consumables is a major issue in the healthcare sector. “From a citizen’s point of view, pricing is one of the big issues. Some essential drugs are regulated only by MRP declaration, without real price control. Consumables are one of the biggest challenges in the industry. We studied hospital consumables’ purchase prices vs. MRP across sectors and found large margins.”

An IV (intravenous) set, he said, is purchased at Rs 11.05 but the MRP is Rs 325. “So there’s a margin of 2841 per cent… The nebulizer/oxygen mask items are purchased at Rs 40 or Rs 45 but sold at Rs 650 or 715: a margin of roughly 1300–1600 per cent. Look at miscellaneous disposable consumables (masks, catheters, IV cannula): purchase prices are Rs 197, Rs 29, Rs 22 against MRPs of Rs 500, Rs 300, Rs 424,” he said.

“After studying this, I submitted a policy proposal to the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, saying we need intervention. I am requesting that these primary in-hospital devices/consumables be brought under Section 4 of the Drug Price Control Order (DPCO) 2013 (under the Essential Commodities Act, 1955) for regulation, given such margins,” Mundhe told .

He said in the last three months, the Maharashtra FDA has carried out 2,485 inspections against pharmaceutical firms and suspended 230 licences.

Story continues below this ad

“For pharmacies and medical shops, we inspected 11,780 establishments, suspended licences of 2,075 and cancelled licences of 394,” Mundhe said.

In his post on X, the IAS officer said the price of consumables is not an elective purchase. “Patients cannot compare prices, seek alternatives, or question a number printed on a box while receiving care and the MRP itself is often fixed upstream by manufacturers and distributors, disconnected from the trade price by a wide, unexplained margin. The result is a system where the party bearing the cost has the least information to evaluate it,” he said.